project id: TCGA-PRAD; case submitter id: TCGA-KC-A7F3; selected normal wgs: true; source center: 23; state: released; a260 a280 ratio: 1.96; normal tumor genotype snp match: Yes; ribosomal rna 28s 16s ratio: 1.51; rna integrity number: 8.4; age at index: 67; days to birth: -24676; ethnicity: not hispanic or latino; gender: male; race: white; vital status: Alive; year of birth: 1946; age at diagnosis: 24676; ajcc clinical m: M0; ajcc clinical t: T1c; ajcc pathologic n: N0; ajcc pathologic t: T2c; classification of tumor: not reported; days to diagnosis: 0; days to last follow up: 665.0; icd 10 code: C61; last known disease status: not reported; morphology: 8140/3; primary diagnosis: Adenocarcinoma, NOS; primary gleason grade: Pattern 3; prior malignancy: no; prior treatment: No; progression or recurrence: not reported; secondary gleason grade: Pattern 4; site of resection or biopsy: Prostate gland; synchronous malignancy: No; tissue or organ of origin: Prostate gland; tumor grade: Not Reported; year of diagnosis: 2013; treatment or therapy: no; alcohol history: Not Reported; is ffpe: false; composition: Not Reported; days to collection: 195; initial weight: 270.0; sample id: 8080e9a4-a7bd-47a6-ba4c-9437a868507d; sample submitter id: TCGA-KC-A7F3-01A; portion id: 863dd146-6543-4807-aa92-17efe5eb32db; portion submitter id: TCGA-KC-A7F3-01A-21; slide id: 4ab11652-9ba5-4d7e-8e04-ff75c57835cc; slide submitter id: TCGA-KC-A7F3-01A-02-TSB; percent lymphocyte infiltration: 2.0; percent monocyte infiltration: 0.0; percent necrosis: 0.0; percent neutrophil infiltration: 0.0; percent normal cells: 20.0; percent stromal cells: 20.0; percent tumor cells: 60.0; percent tumor nuclei: 60.0; section location: TOP;